<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert M Silver, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynn L Simpson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 04, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Placenta accreta spectrum (PAS) is a general term used to describe abnormal trophoblast invasion into the myometrium, and sometimes to or beyond the serosa. It is clinically important because the placenta does not spontaneously separate at delivery and attempts at manual removal result in hemorrhage, which can be life-threatening and usually necessitates hysterectomy. The pathogenesis of most cases of PAS is thought to be placental implantation at an area of defective decidualization caused by preexisting damage to the endometrial-myometrial interface. The most important risk factor for PAS is a placenta previa after a prior cesarean delivery.
        </p>
        <p>
         This topic will discuss the clinical features, diagnosis, and potential consequences of PAS. Management of patients with a PAS is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">
          "Placenta accreta spectrum: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1822804338">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAS (formerly called morbidly adherent placenta or abnormally invasive placenta) is a broad term that traditionally includes three subtypes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Placenta accreta (or creta)
         </strong>
         – Anchoring placental villi attach to the myometrium (rather than decidua).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Placenta increta
         </strong>
         – Anchoring placental villi penetrate into the myometrium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Placenta percreta
         </strong>
         – Anchoring placental villi penetrate through the myometrium to the uterine serosa or adjacent organs.
        </p>
        <p>
        </p>
        <p>
         The International Federation of Gynecology and Obstetrics (FIGO) Placenta Accreta Spectrum Disorders Diagnosis and Management Expert Consensus Panel created a classification system that describes PAS as follows [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade 1 – abnormally adherent placenta: placenta adherent or creta
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade 2 – abnormally invasive placenta: increta
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade 3 – abnormally invasive placenta: percreta
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         subtype 3a – limited to the uterine serosa
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         subtype 3b – urinary bladder invasion
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         subtype 3c – invasion of other pelvic tissue/organs
        </p>
        <p>
        </p>
        <p>
         This system also includes clinical and histologic criteria for each grade and subtype. Other multitiered grading systems based on the depth of invasion have been proposed [
         <a href="#rid2">
          2
         </a>
         ], but none have widespread acceptance.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a 2019 systematic review that included 7001 cases of PAS among nearly 5.8 million births, the overall pooled prevalence was 0.17 percent (range 0.01 to 1.1 percent) [
         <a href="#rid3">
          3
         </a>
         ]. This is markedly higher than the 0.003 percent prevalence in the United States in the 1950s [
         <a href="#rid4">
          4,5
         </a>
         ]. The marked increase in PAS, which began in the 1980s and 1990s and has been observed worldwide, is attributed to the increasing prevalence of cesarean delivery in recent decades [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="local">
          'Risk factors'
         </a>
         below.)
        </p>
        <p>
         Placenta accreta is much more common than placenta increta and percreta. In the same systematic review, the types and frequencies of abnormal placentation were [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placenta accreta – 63 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placenta increta – 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placenta percreta – 22 percent
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3937332">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of PAS is not known with certainty but increasing data support the roles of uterine remodeling during postoperative scar formation (primarily cesarean birth) and preexisting uterine pathology (eg, rupture, dehiscence, adhesions) [
         <a href="#rid7">
          7-9
         </a>
         ]. In this model of Jauniaux et al, absence of reepithelialization to the endometrium, failure of normal decidualization and loss of the normal subdecidual myometrium (myofibers, spiral arteries, junctional zone between the endometrium and superficial myometrium) and/or their replacement by scar tissue allows extravillous trophoblast to migrate close to the uterine serosa and reach the large arterial branches (radial and/or arcuate arteries) of the uterine artery and contribute to their transformation [
         <a href="#rid9">
          9,10
         </a>
         ]. High-volume high-velocity blood flow from the abnormally dilated deep arterial uterine circulation leads to formation of placental lacunae and progressive fibrinoid deposition between the tip of most anchoring villi and the underlying uterine wall and around all deeply implanted villi at the uteroplacental interface. These changes are associated with distortion of the Nitabuch membrane or stria and the loss of parts of the physiological site of detachment of the placenta from the uterine wall.
        </p>
        <p>
         Placenta percreta is not caused by trans-serosal villous invasion. Most, if not all, cases appear to result from complete or partial uterine rupture, uterine dehiscence, or adhesions between the anterior lower uterine segment and posterior bladder wall that allow extravillous trophoblast direct access to the serosa and beyond [
         <a href="#rid8">
          8,11
         </a>
         ]. Confirmed cases of placenta percreta as early as 16 weeks of gestation suggest that, at least in some cases, the "die is cast" at implantation as to whether an accreta, increta, or percreta will develop and that increasing depth of invasion is not related to increasing duration of gestation. Also, numerous cases of artifactual "percreta" have been reported where the placenta was contained within the uterus at the start of the case but extruded through a uterine dehiscence after surgical manipulation.
        </p>
        <p>
         This model is supported by the observation that 80 percent of patients with PAS have a history of previous cesarean delivery, curettage, and/or myomectomy [
         <a href="#rid11">
          11
         </a>
         ]. In rare cases, uterine pathology, such as bicornuate uterus, adenomyosis, submucous fibroids, myotonic dystrophy, or effects of previous radiation therapy, may be associated with microscopic endometrial defects that interfere with normal biological endometrial functions and thereby allow abnormal placental attachment [
         <a href="#rid12">
          12
         </a>
         ]. This may explain the rare occurrence of PAS in primigravid patients with no history of uterine surgery.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H3937600">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important risk factor for development of a PAS is placenta previa after a prior cesarean delivery. In a prospective study including 723 women with placenta previa undergoing cesarean delivery, the frequency of PAS increased with an increasing number of cesarean deliveries as follows [
         <a href="#rid13">
          13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First (primary) cesarean birth, 3 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second cesarean birth, 11 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third cesarean birth, 40 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fourth cesarean birth, 61 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fifth or greater cesarean birth, 67 percent
        </p>
        <p>
        </p>
        <p>
         In the absence of placenta previa, the frequency of a PAS in women undergoing cesarean delivery was much lower [
         <a href="#rid13">
          13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First (primary) cesarean birth, 0.03 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second cesarean birth, 0.2 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third cesarean birth, 0.1 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fourth or fifth cesarean birth, 0.8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sixth or greater cesarean birth, 4.7 percent
        </p>
        <p>
        </p>
        <p>
         Other risk factors include a history of uterine surgery (eg, myomectomy entering the uterine cavity, hysteroscopic removal of intrauterine adhesions, cornual resection of ectopic pregnancy, dilation and curettage, endometrial ablation [
         <a href="#rid14">
          14
         </a>
         ]), maternal age greater than 35 years, multiparity, history of pelvic irradiation, manual removal of the placenta, postpartum endometritis, infertility and/or infertility procedures (eg, especially transfer of cryopreserved embryos), and possibly multiple gestations [
         <a href="#rid15">
          15-24
         </a>
         ]. Basal plate myometrial fibers (BPMF) in the delivered placenta may be reported by the pathologist and appear to be a risk factor for retained placenta or PAS in the index and subsequent pregnancies, especially when BPMF are prominent [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
         Cesarean scar pregnancy had been considered a risk factor for PAS, but these two conditions likely represent a continuum of the same disease, given similar histology [
         <a href="#rid16">
          16,27,28
         </a>
         ]. An ongoing cesarean scar pregnancy is now considered a precursor of low-lying placenta, placenta previa, placenta previa accreta, or rarely uterine rupture [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/131912.html" rel="external">
          "Cesarean scar pregnancy"
         </a>
         .)
        </p>
        <p>
         Consideration of risk factors other than previous cesarean is particularly important in women in their first ongoing pregnancy and those without placenta previa. Assisted reproductive technology and a previous uterine procedure appear to be risk factors for PAS without placenta previa [
         <a href="#rid30">
          30
         </a>
         ]. However, it is important to note that, in a multivariate analysis, placenta previa appeared to be an independent risk factor for PAS (odds ratio [OR] 54, 95% CI 18-166), while prior uterine surgery was not (OR 1.5, 95% CI 0.4-5.1) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study limited to primiparous women with invasive placentation, the relative risk [RR] of invasive placentation for those with a history of one or two previous gynecologic procedures (including suction curettage for pregnancy termination) was RR 1.5 (95% CI 1.1-1.9) and RR 2.7 (95% CI 1.7-4.4), respectively [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective study, more than half of the cases of PAS occurred in women without the combination of placenta previa and ≥1 prior cesarean; these patients had better maternal and neonatal outcomes than those with both high-risk factors [
         <a href="#rid32">
          32
         </a>
         ]. However, some women without both previa and prior cesarean may not have had PAS since there was no definitive histologic diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review, pregnancies complicated by PAS without previa were more likely to be associated with IVF, prior curettage, and myomectomy, and much less likely to be associated with prior cesarean birth [
         <a href="#rid33">
          33
         </a>
         ]. Pregnancies with PAS without previa had better maternal outcomes than PAS with previa, possibly because increta and percreta appear to be less prevalent in the absence of previa [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3939541">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ideally, PAS is first suspected because of findings on obstetric ultrasound examination while the patient is asymptomatic. It is often diagnosed during prenatal sonographic screening of women with a placenta previa or a low anterior placenta and prior uterine surgery. In women with less prominent risk factors for abnormal placental attachment, it may be an incidental finding during routine ultrasound examination, and sometimes the diagnosis is not made until delivery of the placenta [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="local">
          'Prenatal screening and diagnosis'
         </a>
         below.)
        </p>
        <p>
         The first clinical manifestation of PAS is often profuse, life-threatening hemorrhage that occurs at the time of attempted manual placental separation. In contrast to a simple retained placenta, part or all of the placenta remains firmly attached to the uterine cavity, and no plane of separation can be developed. If placental tissue has invaded to the anterior serosa or bladder, profuse, life-threatening hemorrhage can occur during attempts to dissect the bladder off of the lower uterine segment. However, PAS also may present as antenatal bleeding in the setting of placenta previa.
        </p>
        <p>
         In a systematic review, the clinical characteristic of placenta percreta on presentation were sudden severe pelvic-suprapubic-abdominal pain (41 percent), vaginal bleeding (25 percent), both pain and bleeding (7 percent), and preterm labor or prelabor rupture of membranes (7 percent) [
         <a href="#rid8">
          8
         </a>
         ]. In contrast to these findings, bleeding is the most common symptom and pain is rare in our experience; thus, the diagnosis of PAS should still be considered in patients with bleeding but no or minimal pain.
        </p>
        <p class="headingAnchor" id="H260805669">
         <span class="h2">
          Possible laboratory findings
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biomarkers
         </strong>
         – No biomarker is clinically useful. An elevated maternal serum alphafetoprotein (MSAFP) level (&gt;2 or 2.5 multiples of the median) has been observed in patients with abnormal placental implantation, but it is an inconsistent finding and not useful by itself for diagnosis. Moreover, a normal MSAFP does not exclude the diagnosis [
         <a href="#rid31">
          31,35,36
         </a>
         ]. Other biomarkers (eg, pregnancy-associated plasma protein A, free beta-human chorionic gonadotropin) have also been associated with PAS and are also not useful diagnostically because of their very low positive predictive value. Proteomic markers in maternal blood show promise for the diagnosis of PAS [
         <a href="#rid37">
          37
         </a>
         ]; however, the test needs extensive validation before it can be recommended for clinical use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematuria
         </strong>
         – Placenta percreta with bladder invasion can cause hematuria during pregnancy. A literature review including 54 cases of placenta percreta invading the bladder reported that 17 (31 percent) were associated with hematuria [
         <a href="#rid38">
          38
         </a>
         ]. Cystoscopy was performed in 12 patients but was not useful for making a preoperative diagnosis. This may be due to microscopic invasion of the bladder that is not visible on cystoscopy but can lead to hematuria.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15006491">
         <span class="h2">
          Consequences
         </span>
         <span class="headingEndMark">
          —
         </span>
         When removal of the placenta is attempted after delivery, the lack of a normal plane of cleavage between the placental basal plate and the uterine wall results in major hemorrhage. The hemorrhage is especially severe with more invasive placentation because of greater hypervascularity of the placental bed (ie, local neovascularization and vasodilatation) [
         <a href="#rid39">
          39-41
         </a>
         ]. Potential sequelae of massive hemorrhage include disseminated intravascular coagulopathy, adult respiratory distress syndrome, renal failure, unplanned surgery, and death, as well as potential complications from transfusion.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripartum hysterectomy and other morbidity
         </strong>
         – PAS is a common indication for peripartum hysterectomy, either to prevent or to control postpartum hemorrhage. Transfusion is the most common associated morbidity, followed by complications related to surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a systematic review including 7001 PAS cases, peripartum hysterectomy was performed in 52.2 percent (95% CI 38.3-66.4), and blood transfusion was required in 46.9 percent (95% CI 34.0-59.9) [
         <a href="#rid3">
          3
         </a>
         ]. Of note, PAS was not histologically confirmed in cases without hysterectomy. Outcomes may vary among populations and may be worse for histologically confirmed cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a series of 356 patients with PAS, the most common morbidity other than transfusion was bladder injury, which occurred in 5 percent of cases [
         <a href="#rid42">
          42
         </a>
         ]. The following complications occurred in ≤2 percent of cases: urinary tract damage, genitourinary fistula, bowel damage, thrombotic event, wound infection, hemorrhagic shock, cardiac arrest, and renal failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased maternal morbidity with more severe disease
         </strong>
         – Composite maternal morbidity is especially high with placenta percreta (86 versus 27 percent with accreta [
         <a href="#rid43">
          43
         </a>
         ]). Delivery and hysterectomy are often complicated because extrauterine anatomic structures, including blood vessels in the pelvis, may be adherent to the placenta. If an accreta rather than a percreta is suspected before delivery, preoperative preparation for delivery may be inadequate; however, severe maternal morbidity can occur despite multidisciplinary planning, management in a referral center, and antenatal suspicion of percreta.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonatal morbidity
         </strong>
         – Preterm birth and small for gestational age infants appear to be more common in pregnancies complicated by PAS [
         <a href="#rid44">
          44
         </a>
         ]. Neonatal outcome is strongly related to gestational age at delivery but does not appear to be significantly affected by depth of placental invasion (accreta versus percreta) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mortality
         </strong>
         – Maternal and perinatal death are uncommon in case series from tertiary care centers where multispecialty expertise is usually available; however, these reports are prone to selection bias [
         <a href="#rid46">
          46-48
         </a>
         ]. In a series of 442 patients with suspected PAS in the International Society of PAS database (2008 to 2019), there were no maternal deaths despite blood loss as high as 20,000 mL and 88 patients with placental invasion into the bladder or beyond (eg, pelvic side wall) [
         <a href="#rid49">
          49
         </a>
         ]. Nonetheless, the authors are aware of maternal deaths that occur each year in high-income countries, most of which are unreported.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3863617759">
         <span class="h2">
          Postpartum placental histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postpartum histologic findings show placental villi anchored directly on, or invading into or through the myometrium, without an intervening decidual plate. The placenta is characterized as an accreta  (
         <a class="graphic graphic_picture graphicRef60800" href="/z/d/graphic/60800.html" rel="external">
          picture 1
         </a>
         ), increta  (
         <a class="graphic graphic_picture graphicRef73597" href="/z/d/graphic/73597.html" rel="external">
          picture 2
         </a>
         ), or percreta, depending on the greatest depth of myometrial invasion (superficial, deep, or penetrating the entire uterine wall), as the degree of villous adhesion or invasion is not always uniform [
         <a href="#rid12">
          12
         </a>
         ]. The diagnosis of focal accreta may be confirmed in the absence of hysterectomy by identification of these findings in uterine curettings or in fragments of myometrium adherent to the placenta.
        </p>
        <p>
         One group has developed a protocol for gross and microscopic pathologic examination of cases of suspected PAS, including correlation with clinical and radiologic findings [
         <a href="#rid50">
          50
         </a>
         ]. The standard, detailed examination can be helpful for postpartum discussions with patients and for research.
        </p>
        <p class="headingAnchor" id="H1042633652">
         <span class="h1">
          PRENATAL SCREENING AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prenatal screening and diagnosis are important so that the patient can be counseled about the suspected placental abnormality and an appropriate site and plan for delivery can be developed. Preoperative preparation, including availability of surgical and radiological expertise, blood components for transfusion, and appropriate equipment, improves outcome. In a meta-analysis, women with a predelivery diagnosis of PAS had fewer emergency cesarean births (31.4 versus 53.5 percent; OR 0.37, 95% CI 0.21-0.67; 9 studies), less blood loss (2.27 versus 2.00 liters; mean difference 0.65, 95% CI -1.17 to -0.13; 24 studies) and fewer red cell transfusions (4.13 versus 6.51 units; mean difference 1.96, 95% CI -3.25 to -0.68; 17 studies) than women in whom the condition was diagnosed at delivery [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">
          "Placenta accreta spectrum: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3022736366">
         <span class="h2">
          Candidates and procedure for screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with a placenta previa or a low anterior placenta and prior uterine surgery should have thorough transabdominal and transvaginal sonographic evaluation of the interface between the placenta and myometrium between approximately 18 and 24 weeks of gestation. At this gestational age, the prenatal diagnosis of PAS can be made or ruled out with close to 90 percent accuracy, although in population-based studies, prenatal diagnosis was not made in one-half to two-thirds of cases [
         <a href="#rid52">
          52-54
         </a>
         ]. Consistent use of a targeted screening protocol may be helpful [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Ultrasound follow-up of patients with placenta previa or low anterior placenta is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6809.html" rel="external">
          "Placenta previa: Management", section on 'Monitoring placental position'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1073084839">
         <span class="h2">
          Prenatal diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAS is highly likely in patients with placenta previa or a low lying placenta after one or more previous cesarean deliveries plus imaging studies suggestive of abnormal implantation, as described below (see
         <a class="local">
          'Ultrasound findings'
         </a>
         below). The diagnosis can be reasonably excluded when imaging studies suggest normal placental implantation.
        </p>
        <p>
         Based on our experience with the management of hundreds of cases, we have found that placental lacunae (which appear as intraplacental sonolucent spaces) and disruption of the interface between the bladder wall-uterine serosa (ie, bladder line) are the most reliable diagnostic sonographic findings. Color flow Doppler demonstrating turbulent ("chaotic") lacunar flow and/or bridging vessels is a valuable confirmatory finding. If the ultrasound studies are inconclusive or ambiguous (eg, when the region of concern is not the anterior lower uterine segment, such as after myomectomy [
         <a href="#rid56">
          56
         </a>
         ]), magnetic resonance imaging (MRI) may be performed to clarify the diagnosis if this will affect patient management; however, the utility of the additional information gained by MRI is uncertain. (See
         <a class="local">
          'Ultrasound findings'
         </a>
         below and
         <a class="local">
          'Color Doppler'
         </a>
         below and
         <a class="local">
          'Magnetic resonance imaging (MRI)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3939740">
         <span class="h3">
          Ultrasound findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the second and third trimesters, the following transabdominal and transvaginal sonographic findings have been associated with PAS; all of the findings need not be present [
         <a href="#rid57">
          57-59
         </a>
         ]. Many of the findings can be obscured with posterior placental location.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiple placental lacunae
         </strong>
         – Multiple large, irregular intraplacental sonolucent spaces (ie, placental lacunae) in the center of a lobule or cotyledon adjacent to the involved myometrium replace normal placental homogeneity and give the placenta a "moth-eaten" appearance. The risk of PAS is highest in the setting of greater than three large lacunae with irregular borders and high velocity and/or turbulent flow (&gt;15 cm/s). In a meta-analysis, sensitivity of lacunae for identifying placenta accreta, increta, and percreta was approximately 75, 89, and 76 percent, respectively, and specificities were approximately 97, 98, and 99 percent, respectively [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A normal placenta can have vascular lakes, typically a few small, sonolucent spaces with a regular shape and normal underlying myometrial thickness  (
         <a class="graphic graphic_diagnosticimage graphicRef117180" href="/z/d/graphic/117180.html" rel="external">
          image 1
         </a>
         ). In contrast, the placental lacunae in PAS are more numerous and irregular in shape, and the underlying myometrium may be thinned  (
         <a class="graphic graphic_diagnosticimage graphicRef117181" href="/z/d/graphic/117181.html" rel="external">
          image 2
         </a>
         ). Although a partial hydatidiform mole has a "Swiss-cheese" appearance  (
         <a class="graphic graphic_diagnosticimage graphicRef79947" href="/z/d/graphic/79947.html" rel="external">
          image 3
         </a>
         ), the sonolucent spaces are small, distributed throughout the placenta, and have no blood flow.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Placental lacunae can be described in terms of a score: 0 for no lacuna, 1+ for 1 to 3 lacunae, 2+ for 4 to 6 lacunae, and 3+ for &gt;6 lacunae. A high lacunae score (3+) increases the likelihood of PAS and has been associated with a greater than fivefold increase in risk of hysterectomy for PAS at birth [
         <a href="#rid61">
          61
         </a>
         ]. However, clinical utility remains uncertain and the predictive value is highly influenced by the a priori risk based on clinical factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disruption of the bladder line
         </strong>
         – Loss or disruption of the normally continuous white line representing the bladder wall-uterine serosa interface (termed the "bladder line") can be caused by placenta percreta or neovascularity related to placenta accreta or increta.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Loss of the clear zone
         </strong>
         – The normal hypoechoic area behind the placenta (termed the "clear space" or "clear zone")  (
         <a class="graphic graphic_diagnosticimage graphicRef63825" href="/z/d/graphic/63825.html" rel="external">
          image 4
         </a>
         ) may be missing or irregular. This sign can be obscured by direct pressure from the ultrasound probe and bladder filling [
         <a href="#rid12">
          12
         </a>
         ]. It can also be obscured with advancing gestational age.
        </p>
        <p class="bulletIndent1">
         In a meta-analysis, sensitivity of loss of the clear zone in identifying placenta accreta, increta, and percreta was approximately 75, 92, and 88 percent, respectively; specificity was approximately 92, 77, and 71 percent, respectively [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myometrial thinning
         </strong>
         – The retroplacental myometrium can be thin (&lt;1 mm) due to either a prior hysterotomy scar or placental invasion. When the placenta overlies the region of thinning, then it is important to look for other signs of PAS  (
         <a class="graphic graphic_diagnosticimage graphicRef83270" href="/z/d/graphic/83270.html" rel="external">
          image 5A
         </a>
         ). For example, if the placenta is seen extending through the myometrium (ie, percreta), then it is clearly an invasive placenta. However, it can be difficult (or even impossible) to sonographically distinguish placenta accreta from increta as the thin myometrium impedes assessment of the depth of invasion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal vascularity
         </strong>
         – Vessels that extend from the placenta through the myometrium either into the bladder or through the serosa elsewhere are a clear sign of placenta percreta.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal uterine contour
         </strong>
         – An abnormal uterine contour may be present whereby a portion of the uterus attached to the abnormally adherent placenta balloons into the bladder due to weakness of the underlying thin myometrium. This is also called placental bulge.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exophytic mass
         </strong>
         – A focal mass that breaks through the uterine serosa, usually extending into the bladder, is a sign of placenta percreta.
        </p>
        <p>
        </p>
        <p>
         In a meta-analysis of 20 studies of prenatal sonographic identification of placenta accreta, increta, and percreta, the sensitivity for depth of placental invasion was approximately 91, 93, and 81 percent, respectively, and specificity was approximately 97, 98, and 99 percent, respectively [
         <a href="#rid60">
          60
         </a>
         ]. Foreknowledge of the clinical setting may have contributed to these high figures as performance was much lower (sensitivity 53 percent) in a study in which a diverse group of ultrasound providers was blinded to the patient's clinical status (eg, clinical suspicion for accreta, prior knowledge of risk factors) [
         <a href="#rid62">
          62
         </a>
         ]. Other limitations of the studies are that histopathologic correlation was not always performed or adequately described. In addition, it is difficult to compare results of studies since nomenclature is not standardized and sonographic assessment of the depth of villous invasiveness in the uterine wall is subjective, without established ultrasound criteria for distinguishing between different grades of adherent and invasive placentation [
         <a href="#rid63">
          63
         </a>
         ]. Standardized terminology and criteria have been proposed by expert groups but are not widely used in the United States [
         <a href="#rid1">
          1,64-67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5133002">
         <span class="h4">
          Color Doppler
         </span>
         <span class="headingEndMark">
          —
         </span>
         Color Doppler is useful for confirming the diagnosis of PAS when used in conjunction with the other ultrasound findings described above. Specific findings on color Doppler ultrasonography that suggest this diagnosis include  (
         <a class="graphic graphic_diagnosticimage graphicRef83270 graphicRef97402" href="/z/d/graphic/83270.html" rel="external">
          image 5A-B
         </a>
         ) [
         <a href="#rid68">
          68-72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Turbulent lacunar blood flow (&gt;15 cm/sec)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bridging vessels
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffuse or focal intraparenchymal flow
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypervascularity of serosa-bladder interface
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prominent subplacental venous complex
        </p>
        <p>
        </p>
        <p>
         Bridging vessels are placental vessels that extend through the myometrium and beyond the serosa into the bladder (or other organs). They should not be mistaken for bladder varices, which are enlarged maternal bladder veins and often seen in normal pregnancy.
        </p>
        <p>
         In the meta-analysis described above, lacunar flow had sensitivities of approximately 81, 84, and 45 percent for the detection of placenta accreta, increta, and percreta, respectively; specificity was approximately 84, 80, and 75 percent, respectively [
         <a href="#rid60">
          60
         </a>
         ]. Uterovesical hypervascularity for the detection of placenta accreta had low sensitivity (12 percent), but higher sensitivity for placenta increta (94 percent) and percreta (86 percent); specificity was 91, 88, and 88 percent, respectively. However, assessment of the performance of any individual sign is not clinically relevant since observation of one sign is likely to increase the chance of detecting others, and the signs are not evaluated in isolation.
        </p>
        <p class="headingAnchor" id="H3878483344">
         <span class="h3">
          Utility of additional imaging techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of the following imaging techniques in diagnosis of PAS has not been clearly determined.
        </p>
        <p class="headingAnchor" id="H3858442282">
         <span class="h4">
          Magnetic resonance imaging (MRI)
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI may be more useful than ultrasound in three clinical scenarios: (1) evaluation of a possible posterior PAS because the bladder cannot be used to help clarify the placental-myometrial interface; (2) assessment of the depth of myometrial and parametrial involvement and, if the placenta is anterior, bladder involvement; and (3) evaluation of the myometrium and placenta at the most lateral portions of the hysterotomy as this area is not well visualized by transvaginal ultrasound, which images the central portion of the myometrium and placenta [
         <a href="#rid73">
          73,74
         </a>
         ]. However, increased accuracy beyond that noted with ultrasound is unproven [
         <a href="#rid75">
          75
         </a>
         ], and one study noted that MRI was just as likely to change a correct ultrasound-based PAS diagnosis to an incorrect MRI diagnosis as it was to correctly revise an incorrect ultrasound-based PAS diagnosis [
         <a href="#rid76">
          76
         </a>
         ]. Key factors for high diagnostic performance are ensuring that MRIs are interpreted in conjunction with the ultrasound findings, and both are interpreted by physicians with expertise in this area.
        </p>
        <p>
         If performed, one group considers 24 to 30 weeks the ideal gestational age for imaging invasive placentation with MRI as false positives and negatives are more likely earlier and later in gestation [
         <a href="#rid77">
          77
         </a>
         ]. MRI is safe for the fetus, although the use of gadolinium, which may improve diagnostic performance [
         <a href="#rid78">
          78
         </a>
         ], is generally avoided in pregnancy due to neurologic, inflammatory, and dermatologic complications to the fetus [
         <a href="#rid79">
          79
         </a>
         ], as well as unknown effects of the small amount of gadolinium deposition in the fetus [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">
          "Diagnostic imaging in pregnant and lactating patients", section on 'Use of gadolinium'
         </a>
         .)
        </p>
        <p>
         A panel of experts concluded that the following MRI findings are the most accurate predictors of placenta accreta  (
         <a class="graphic graphic_diagnosticimage graphicRef81005 graphicRef61154 graphicRef97403" href="/z/d/graphic/81005.html" rel="external">
          image 6A-C
         </a>
         ) [
         <a href="#rid81">
          81
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uterine bulging into the bladder ("placental/uterine bulge")
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interruption of the bladder wall
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of retroplacental hypointense line on T2W images
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal vascularization of the placental bed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dark intraplacental bands on T2W imaging ("T2-dark bands")
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myometrial thinning
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal exophytic mass
        </p>
        <p>
        </p>
        <p>
         An increased number of positive findings is predictive of a worse prognosis. In a study of 100 women with placenta previa who underwent MRI, presence of ≥3 of 15 MRI features considered suggestive of PAS was associated with an odds ratio (OR) &gt;19 for a complicated delivery, and presence of ≥6 was associated with an OR &gt;90 for massive bleeding at delivery [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         In a 2018 systematic review and meta-analysis of 20 studies totaling 1080 pregnancies with ultrasound suspicion or presence of clinical risk factors for PAS, MRI had high diagnostic accuracy: for detection of placenta accreta, increta, and percreta, sensitivity was approximately 94, 100, and 87 percent, respectively; the corresponding values for specificity were approximately 99, 97, and 97 percent, respectively [
         <a href="#rid83">
          83
         </a>
         ]. The accuracy of diagnosis with MRI is highly dependent on the expertise and experience of the radiologist interpreting the imaging study.
        </p>
        <p class="headingAnchor" id="H27505539">
         <span class="h4">
          Three-dimensional power Doppler ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three-dimensional ultrasound has been used successfully for evaluation of PAS [
         <a href="#rid70">
          70,84
         </a>
         ]. Diagnostic criteria include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irregular intraplacental vascularization with tortuous confluent vessels crossing placental width.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypervascularity of uterine serosa-bladder wall interface.
        </p>
        <p>
        </p>
        <p>
         In a study of 187 patients with placenta previa and a history of uterine surgery, 97 of 146 patients without confirmed PAS had none of the five two- or three-dimensional ultrasound findings associated with PAS and the remaining 49 patients had only one finding [
         <a href="#rid84">
          84
         </a>
         ]. By comparison, none of the 41 patients with PAS (placenta accreta or worse) had zero or one of these findings; five had two findings and the remainder had three to five findings.
        </p>
        <p>
         Another cohort study of 89 women noted 100 percent sensitivity with 92 percent specificity for three-dimensional power Doppler in the detection of PAS [
         <a href="#rid85">
          85
         </a>
         ]. These findings are promising and should be assessed in larger populations to evaluate consistency and generalizability.
        </p>
        <p class="headingAnchor" id="H4204802564">
         <span class="h4">
          First-trimester ultrasound examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAS should be suspected if ultrasound examination before 9 weeks reveals implantation of the gestational sac in the lower anterior segment of the uterus, particularly in the niche of the prior cesarean delivery scar [
         <a href="#rid86">
          86-91
         </a>
         ]. Subsequent placental development in this area should also raise suspicion for PAS. In a retrospective cohort study of 467 women with a previous cesarean, transvaginal ultrasound between 11 and 14 weeks of gestation showing the placenta next to, on, or inside the hysterotomy scar potentially identified most of the eight cases of PAS [
         <a href="#rid91">
          91
         </a>
         ]. Indeed, cesarean scar pregnancy is associated with an extremely high risk of subsequent PAS. Prospective and larger studies are needed to determine sensitivity and specificity and elucidate how this finding might influence patient counseling and follow-up in the future. (See
         <a class="medical medical_review" href="/z/d/html/131912.html" rel="external">
          "Cesarean scar pregnancy"
         </a>
         .)
        </p>
        <p>
         The characteristic second-trimester findings of placental lacunae (which appear as intraplacental sonolucent spaces with turbulent blood flow), disruption of the interface between the bladder wall-uterine serosa (ie, bladder line), and lower uterine segment (uterovesical, subplacental and/or intraplacental) hypervascularity also may be observed in the late first trimester [
         <a href="#rid92">
          92,93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4020407142">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118733.html" rel="external">
          "Society guideline links: Obstetric hemorrhage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15006693">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition/pathology
         </strong>
         – Placenta accreta spectrum (PAS) is a general term comprising placenta accreta, increta, and percreta. In placenta accreta, the anchoring villi attach to the myometrium; in placenta increta, the villi "invade" into the myometrium; and in placenta percreta, the villi penetrate to or through the uterine serosa and may attach to surrounding organs. (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – PAS is generally a consequence of defective decidualization in an area of scarring caused by previous uterine surgery. Because of the defective decidua, the placenta can attach directly to, and sometimes into or through, the myometrium. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors and prevalence
         </strong>
         – The most important risk factor for PAS is placenta previa after a prior cesarean delivery. PAS occurs in 11 percent of women with a placenta previa and one previous cesarean delivery. The risk increases substantially with increasing numbers of prior cesareans. Previous gynecologic uterine surgery is also a risk factor that should be considered, particularly among primigravidas. (See
         <a class="local">
          'Risk factors'
         </a>
         above and
         <a class="local">
          'Prevalence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Women with a placenta previa or a low anterior placenta and prior uterine surgery should have thorough transabdominal and transvaginal sonographic evaluation of the interface between the placenta and myometrium between approximately 18 and 24 weeks of gestation. At this gestational age, the prenatal diagnosis of PAS can be made or ruled out with close to 90 percent accuracy. The diagnosis can be reasonably excluded when imaging studies suggest normal placental implantation. (See
         <a class="local">
          'Candidates and procedure for screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Ideally, PAS is first suspected because of findings on obstetric ultrasound examination while the patient is asymptomatic. The first clinical manifestation of PAS is either antenatal bleeding or profuse, life-threatening hemorrhage that occurs at the time of attempted manual placental separation. Part or all of the placenta remains strongly adherent to the uterine cavity, and no plane of separation can be developed. Accordingly, it is important to recognize the risk factors for PAS and attempt to make a prenatal diagnosis. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Consequences'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prenatal diagnosis
         </strong>
         – Prenatal diagnosis of PAS is based upon the presence of characteristic findings on ultrasound examination, particularly in patients with placenta previa or a low-lying placenta after one or more previous cesarean deliveries. We have found that placental lacunae (which appear as intraplacental sonolucent spaces  (
         <a class="graphic graphic_diagnosticimage graphicRef97402" href="/z/d/graphic/97402.html" rel="external">
          image 5B
         </a>
         )) and disruption of the interface between the bladder wall-uterine serosa (ie, "bladder line") are the most reliable sonographic diagnostic findings. In addition, the normal hypoechoic area behind the placenta (termed the "clear space" or "clear zone")  (
         <a class="graphic graphic_diagnosticimage graphicRef63825" href="/z/d/graphic/63825.html" rel="external">
          image 4
         </a>
         ) may be missing or irregular, and the retroplacental myometrium may be thin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Color flow Doppler demonstrating turbulent ("chaotic") flow and/or bridging vessels is a valuable confirmatory finding of PAS. (See
         <a class="local">
          'Prenatal diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Placenta percreta is suggested by ballooning of the retroplacental myometrium into the bladder, a retroplacental focal mass that breaks through the uterine serosa (especially if into the bladder), and vessels that extend from the placenta through the myometrium either into the bladder or through the serosa. Placenta percreta with bladder invasion can cause hematuria. (See
         <a class="local">
          'Prenatal diagnosis'
         </a>
         above and
         <a class="local">
          'Possible laboratory findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Magnetic resonance imaging (MRI) is an adjunctive diagnostic tool when the diagnosis is uncertain, the placenta is posterior, or to gauge the extent of placental invasion if this will affect patient management. (See
         <a class="local">
          'Magnetic resonance imaging (MRI)'
         </a>
         above and
         <a class="local">
          'Prenatal screening and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         It is critical to correlate the imaging findings with clinical risk factors since imaging findings are common in normal pregnancies. The predictive value of these findings is considerably higher in pregnancies with clinical risk factors for PAS, such as previa and prior cesarean, than in those without risk factors.
        </p>
        <p class="headingAnchor" id="H225652932">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert Resnik, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, et al. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet 2019; 146:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salmanian B, Shainker SA, Hecht JL, et al. The Society for Pediatric Pathology Task Force grading system for placenta accreta spectrum and its correlation with clinical outcomes. Am J Obstet Gynecol 2022; 226:720.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Bunce C, Grønbeck L, Langhoff-Roos J. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol 2019; 221:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Read JA, Cotton DB, Miller FC. Placenta accreta: changing clinical aspects and outcome. Obstet Gynecol 1980; 56:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Chantraine F, Silver RM, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. Int J Gynaecol Obstet 2018; 140:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Hussein AM, Elbarmelgy RM, et al. Failure of placental detachment in accreta placentation is associated with excessive fibrinoid deposition at the utero-placental interface. Am J Obstet Gynecol 2022; 226:243.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Hecht JL, Elbarmelgy RA, et al. Searching for placenta percreta: a prospective cohort and systematic review of case reports. Am J Obstet Gynecol 2022; 226:837.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Jurkovic D, Hussein AM, Burton GJ. New insights into the etiopathology of placenta accreta spectrum. Am J Obstet Gynecol 2022; 227:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Fox KA, Einerson B, et al. Perinatal assessment of complex cesarean delivery: beyond placenta accreta spectrum. Am J Obstet Gynecol 2023; 229:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta 2008; 29:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol 2018; 218:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohn JR, Shamshirsaz AA, Popek E, et al. Pregnancy after endometrial ablation: a systematic review. BJOG 2018; 125:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nageotte MP. Always be vigilant for placenta accreta. Am J Obstet Gynecol 2014; 211:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timor-Tritsch IE, Monteagudo A, Cali G, et al. Cesarean scar pregnancy is a precursor of morbidly adherent placenta. Ultrasound Obstet Gynecol 2014; 44:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silver RM, Fox KA, Barton JR, et al. Center of excellence for placenta accreta. Am J Obstet Gynecol 2015; 212:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaser DJ, Melamed A, Bormann CL, et al. Cryopreserved embryo transfer is an independent risk factor for placenta accreta. Fertil Steril 2015; 103:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzpatrick KE, Sellers S, Spark P, et al. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS One 2012; 7:e52893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi M, Nakai A, Satoh S, Matsuda Y. Adverse obstetric and perinatal outcomes of singleton pregnancies may be related to maternal factors associated with infertility rather than the type of assisted reproductive technology procedure used. Fertil Steril 2012; 98:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esh-Broder E, Ariel I, Abas-Bashir N, et al. Placenta accreta is associated with IVF pregnancies: a retrospective chart review. BJOG 2011; 118:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin HJ, Patterson JA, Nippita TA, et al. Antecedents of Abnormally Invasive Placenta in Primiparous Women: Risk Associated With Gynecologic Procedures. Obstet Gynecol 2018; 131:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salmanian B, Fox KA, Arian SE, et al. In vitro fertilization as an independent risk factor for placenta accreta spectrum. Am J Obstet Gynecol 2020; 223:568.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller HE, Leonard SA, Fox KA, et al. Placenta Accreta Spectrum Among Women With Twin Gestations. Obstet Gynecol 2021; 137:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linn RL, Miller ES, Lim G, Ernst LM. Adherent basal plate myometrial fibers in the delivered placenta as a risk factor for development of subsequent placenta accreta. Placenta 2015; 36:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heller DS, Wyand R, Cramer S. Recurrence of Basal Plate Myofibers, with Further Consideration of Pathogenesis. Fetal Pediatr Pathol 2019; 38:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pekar-Zlotin M, Melcer Y, Levinsohn-Tavor O, et al. Cesarean Scar Pregnancy and Morbidly Adherent Placenta: Different or Similar? Isr Med Assoc J 2017; 19:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timor-Tritsch IE, Monteagudo A, Cali G, et al. Cesarean scar pregnancy and early placenta accreta share common histology. Ultrasound Obstet Gynecol 2014; 43:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Zosmer N, De Braud LV, et al. Development of the utero-placental circulation in cesarean scar pregnancies: a case-control study. Am J Obstet Gynecol 2022; 226:399.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugai S, Yamawaki K, Sekizuka T, et al. Pathologically diagnosed placenta accreta spectrum without placenta previa: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2023; 5:101027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung TH, Shau WY, Hsieh CC, et al. Risk factors for placenta accreta. Obstet Gynecol 1999; 93:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kayem G, Seco A, Beucher G, et al. Clinical profiles of placenta accreta spectrum: the PACCRETA population-based study. BJOG 2021; 128:1646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hessami K, Salmanian B, Einerson BD, et al. Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis. Obstet Gynecol 2022; 140:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carusi DA, Fox KA, Lyell DJ, et al. Placenta Accreta Spectrum Without Placenta Previa. Obstet Gynecol 2020; 136:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupferminc MJ, Tamura RK, Wigton TR, et al. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1993; 82:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelop C, Nadel A, Frigoletto FD Jr, et al. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1992; 80:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shainker SA, Silver RM, Modest AM, et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol 2020; 223:433.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Washecka R, Behling A. Urologic complications of placenta percreta invading the urinary bladder: a case report and review of the literature. Hawaii Med J 2002; 61:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehrabadi A, Hutcheon JA, Liu S, et al. Contribution of placenta accreta to the incidence of postpartum hemorrhage and severe postpartum hemorrhage. Obstet Gynecol 2015; 125:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelop CM, Harlow BL, Frigoletto FD Jr, et al. Emergency peripartum hysterectomy. Am J Obstet Gynecol 1993; 168:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glaze S, Ekwalanga P, Roberts G, et al. Peripartum hysterectomy: 1999 to 2006. Obstet Gynecol 2008; 111:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morlando M, Schwickert A, Stefanovic V, et al. Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: A multinational database study. Acta Obstet Gynecol Scand 2021; 100 Suppl 1:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcellin L, Delorme P, Bonnet MP, et al. Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta. Am J Obstet Gynecol 2018; 219:193.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gielchinsky Y, Mankuta D, Rojansky N, et al. Perinatal outcome of pregnancies complicated by placenta accreta. Obstet Gynecol 2004; 104:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seet EL, Kay HH, Wu S, Terplan M. Placenta accreta: depth of invasion and neonatal outcomes. J Matern Fetal Neonatal Med 2012; 25:2042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warshak CR, Ramos GA, Eskander R, et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol 2010; 115:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamshirsaz AA, Fox KA, Salmanian B, et al. Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach. Am J Obstet Gynecol 2015; 212:218.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosvenor A, Silver R, Porter TF, Zempolich K. Optimal management of placenta accreta. Am J Obstet Gynecol 2007; 195:S82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Beekhuizen HJ, Stefanovic V, Schwickert A, et al. A multicenter observational survey of management strategies in 442 pregnancies with suspected placenta accreta spectrum. Acta Obstet Gynecol Scand 2021; 100 Suppl 1:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dannheim K, Shainker SA, Hecht JL. Hysterectomy for placenta accreta; methods for gross and microscopic pathology examination. Arch Gynecol Obstet 2016; 293:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugai S, Yamawaki K, Sekizuka T, et al. Comparison of maternal outcomes and clinical characteristics of prenatally vs nonprenatally diagnosed placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2023; 5:101197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzpatrick KE, Sellers S, Spark P, et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG 2014; 121:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailit JL, Grobman WA, Rice MM, et al. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol 2015; 125:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG 2016; 123:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melcer Y, Jauniaux E, Maymon S, et al. Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa. Am J Obstet Gynecol 2018; 218:443.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine D, Hulka CA, Ludmir J, et al. Placenta accreta: evaluation with color Doppler US, power Doppler US, and MR imaging. Radiology 1997; 205:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comstock CH. Antenatal diagnosis of placenta accreta: a review. Ultrasound Obstet Gynecol 2005; 26:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finberg HJ, Williams JW. Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section. J Ultrasound Med 1992; 11:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guy GP, Peisner DB, Timor-Tritsch IE. Ultrasonographic evaluation of uteroplacental blood flow patterns of abnormally located and adherent placentas. Am J Obstet Gynecol 1990; 163:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagani G, Cali G, Acharya G, et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Hussein AM, Thabet MM, et al. The role of transvaginal ultrasound in the third-trimester evaluation of patients at high risk of placenta accreta spectrum at birth. Am J Obstet Gynecol 2023; 229:445.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman ZS, Eller AG, Kennedy AM, et al. Accuracy of ultrasound for the prediction of placenta accreta. Am J Obstet Gynecol 2014; 211:177.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Collins SL, Jurkovic D, Burton GJ. Accreta placentation: a systematic review of prenatal ultrasound imaging and grading of villous invasiveness. Am J Obstet Gynecol 2016; 215:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhide A, Sebire N, Abuhamad A, et al. Morbidly adherent placenta: the need for standardization. Ultrasound Obstet Gynecol 2017; 49:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins SL, Ashcroft A, Braun T, et al. Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet Gynecol 2016; 47:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun T, van Beekhuizen HJ, Morlando M, et al. Developing a database for multicenter evaluation of placenta accreta spectrum. Acta Obstet Gynecol Scand 2021; 100 Suppl 1:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shainker SA, Coleman B, Timor-Tritsch IE, et al. Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum Ultrasound Marker Task Force: Consensus on definition of markers and approach to the ultrasound examination in pregnancies at risk for placenta accreta spectrum. Am J Obstet Gynecol 2021; 224:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou MM, Ho ES, Lee YH. Prenatal diagnosis of placenta previa accreta by transabdominal color Doppler ultrasound. Ultrasound Obstet Gynecol 2000; 15:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twickler DM, Lucas MJ, Balis AB, et al. Color flow mapping for myometrial invasion in women with a prior cesarean delivery. J Matern Fetal Med 2000; 9:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih JC, Palacios Jaraquemada JM, Su YN, et al. Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques. Ultrasound Obstet Gynecol 2009; 33:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkley EM, Abuhamad AZ. Prenatal diagnosis of placenta accreta: is sonography all we need? J Ultrasound Med 2013; 32:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comstock CH, Bronsteen RA. The antenatal diagnosis of placenta accreta. BJOG 2014; 121:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maldjian C, Adam R, Pelosi M, et al. MRI appearance of placenta percreta and placenta accreta. Magn Reson Imaging 1999; 17:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkinen P, Helin-Martikainen HL, Vanninen R, Partanen K. Placenta accreta: imaging by gray-scale and contrast-enhanced color Doppler sonography and magnetic resonance imaging. J Clin Ultrasound 1998; 26:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Oliveira Carniello M, Oliveira Brito LG, Sarian LO, Bennini JR. Diagnosis of placenta accreta spectrum in high-risk women using ultrasonography or magnetic resonance imaging: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2022; 59:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einerson BD, Rodriguez CE, Kennedy AM, et al. Magnetic resonance imaging is often misleading when used as an adjunct to ultrasound in the management of placenta accreta spectrum disorders. Am J Obstet Gynecol 2018; 218:618.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ, et al. MRI of Placenta Accreta, Placenta Increta, and Placenta Percreta: Pearls and Pitfalls. AJR Am J Roentgenol 2017; 208:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millischer AE, Salomon LJ, Porcher R, et al. Magnetic resonance imaging for abnormally invasive placenta: the added value of intravenous gadolinium injection. BJOG 2017; 124:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray JG, Vermeulen MJ, Bharatha A, et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. JAMA 2016; 316:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald RJ, Levine D, Weinreb J, et al. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 2018; 289:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jha P, Pōder L, Bourgioti C, et al. Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders. Eur Radiol 2020; 30:2604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourgioti C, Zafeiropoulou K, Fotopoulos S, et al. MRI prognosticators for adverse maternal and neonatal clinical outcome in patients at high risk for placenta accreta spectrum (PAS) disorders. J Magn Reson Imaging 2019; 50:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Familiari A, Liberati M, Lim P, et al. Diagnostic accuracy of magnetic resonance imaging in detecting the severity of abnormal invasive placenta: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calì G, Giambanco L, Puccio G, Forlani F. Morbidly adherent placenta: evaluation of ultrasound diagnostic criteria and differentiation of placenta accreta from percreta. Ultrasound Obstet Gynecol 2013; 41:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins SL, Stevenson GN, Al-Khan A, et al. Three-Dimensional Power Doppler Ultrasonography for Diagnosing Abnormally Invasive Placenta and Quantifying the Risk. Obstet Gynecol 2015; 126:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comstock CH, Lee W, Vettraino IM, Bronsteen RA. The early sonographic appearance of placenta accreta. J Ultrasound Med 2003; 22:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stirnemann JJ, Mousty E, Chalouhi G, et al. Screening for placenta accreta at 11-14 weeks of gestation. Am J Obstet Gynecol 2011; 205:547.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calí G, Timor-Tritsch IE, Forlani F, et al. Value of first-trimester ultrasound in prediction of third-trimester sonographic stage of placenta accreta spectrum disorder and surgical outcome. Ultrasound Obstet Gynecol 2020; 55:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Happe SK, Rac MWF, Moschos E, et al. Prospective First-Trimester Ultrasound Imaging of Low Implantation and Placenta Accreta Spectrum. J Ultrasound Med 2020; 39:1907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rac MW, Moschos E, Wells CE, et al. Sonographic Findings of Morbidly Adherent Placenta in the First Trimester. J Ultrasound Med 2016; 35:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doulaveris G, Ryken K, Papathomas D, et al. Early prediction of placenta accreta spectrum in women with prior cesarean delivery using transvaginal ultrasound at 11 to 14 weeks. Am J Obstet Gynecol MFM 2020; 2:100183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballas J, Pretorius D, Hull AD, et al. Identifying sonographic markers for placenta accreta in the first trimester. J Ultrasound Med 2012; 31:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abinader RR, Macdisi N, El Moudden I, Abuhamad A. First-trimester ultrasound diagnostic features of placenta accreta spectrum in low-implantation pregnancy. Ultrasound Obstet Gynecol 2022; 59:457.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6759 Version 82.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31173360" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139335" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Society for Pediatric Pathology Task Force grading system for placenta accreta spectrum and its correlation with clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30716286" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9240608" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical risk factors for placenta previa-placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6966777" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Placenta accreta: changing clinical aspects and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29405321" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34461077" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Failure of placental detachment in accreta placentation is associated with excessive fibrinoid deposition at the utero-placental interface.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34973177" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Searching for placenta percreta: a prospective cohort and systematic review of case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35248577" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : New insights into the etiopathology of placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36868338" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Perinatal assessment of complex cesarean delivery: beyond placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18514815" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28599899" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16738145" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Maternal morbidity associated with multiple repeat cesarean deliveries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28952185" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pregnancy after endometrial ablation: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25077458" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Always be vigilant for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24890256" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cesarean scar pregnancy is a precursor of morbidly adherent placenta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25460838" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Center of excellence for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25747133" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cryopreserved embryo transfer is an independent risk factor for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23300807" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22763098" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Adverse obstetric and perinatal outcomes of singleton pregnancies may be related to maternal factors associated with infertility rather than the type of assisted reproductive technology procedure used.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21585640" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Placenta accreta is associated with IVF pregnancies: a retrospective chart review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29324602" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Antecedents of Abnormally Invasive Placenta in Primiparous Women: Risk Associated With Gynecologic Procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32360847" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : In vitro fertilization as an independent risk factor for placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33278284" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Placenta Accreta Spectrum Among Women With Twin Gestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26494605" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Adherent basal plate myometrial fibers in the delivered placenta as a risk factor for development of subsequent placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30588864" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Recurrence of Basal Plate Myofibers, with Further Consideration of Pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28457095" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cesarean Scar Pregnancy and Morbidly Adherent Placenta: Different or Similar?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24357257" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cesarean scar pregnancy and early placenta accreta share common histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34492222" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Development of the utero-placental circulation in cesarean scar pregnancies: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37211089" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pathologically diagnosed placenta accreta spectrum without placenta previa: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10214831" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk factors for placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33393174" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical profiles of placenta accreta spectrum: the PACCRETA population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36075058" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32769646" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Placenta Accreta Spectrum Without Placenta Previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7687756" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Placenta accreta is associated with elevated maternal serum alpha-fetoprotein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1383899" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32199927" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Placenta accreta spectrum: biomarker discovery using plasma proteomics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050959" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Urologic complications of placenta percreta invading the urinary bladder: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25751202" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Contribution of placenta accreta to the incidence of postpartum hemorrhage and severe postpartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8498425" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Emergency peripartum hysterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18310378" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Peripartum hysterectomy: 1999 to 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33713033" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: A multinational database study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29733839" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15339763" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Perinatal outcome of pregnancies complicated by placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22463851" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Placenta accreta: depth of invasion and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20027036" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25173187" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Optimal management of placenta accreta
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33483943" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A multicenter observational survey of management strategies in 442 pregnancies with suspected placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26758078" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Hysterectomy for placenta accreta; methods for gross and microscopic pathology examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37865220" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of maternal outcomes and clinical characteristics of prenatally vs nonprenatally diagnosed placenta accreta spectrum: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23924326" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25730233" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Morbidly adherent placenta treatments and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26227006" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29353034" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9393534" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Placenta accreta: evaluation with color Doppler US, power Doppler US, and MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15971281" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Antenatal diagnosis of placenta accreta: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1522623" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2206064" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Ultrasonographic evaluation of uteroplacental blood flow patterns of abnormally located and adherent placentas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28963728" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37187303" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The role of transvaginal ultrasound in the third-trimester evaluation of patients at high risk of placenta accreta spectrum at birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24631709" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Accuracy of ultrasound for the prediction of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27473003" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Accreta placentation: a systematic review of prenatal ultrasound imaging and grading of villous invasiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28120421" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Morbidly adherent placenta: the need for standardization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26205041" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33811336" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Developing a database for multicenter evaluation of placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33386103" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum Ultrasound Marker Task Force: Consensus on definition of markers and approach to the ultrasound examination in pregnancies at risk for placenta accreta spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10776009" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prenatal diagnosis of placenta previa accreta by transabdominal color Doppler ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11243289" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Color flow mapping for myometrial invasion in women with a prior cesarean delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19173239" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23887942" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prenatal diagnosis of placenta accreta: is sonography all we need?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24373591" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The antenatal diagnosis of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10463645" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : MRI appearance of placenta percreta and placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9460637" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Placenta accreta: imaging by gray-scale and contrast-enhanced color Doppler sonography and magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35041250" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Diagnosis of placenta accreta spectrum in high-risk women using ultrasonography or magnetic resonance imaging: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29572089" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Magnetic resonance imaging is often misleading when used as an adjunct to ultrasound in the management of placenta accreta spectrum disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27762597" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : MRI of Placenta Accreta, Placenta Increta, and Placenta Percreta: Pearls and Pitfalls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27346286" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Magnetic resonance imaging for abnormally invasive placenta: the added value of intravenous gadolinium injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27599330" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30204075" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32040730" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30578609" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : MRI prognosticators for adverse maternal and neonatal clinical outcome in patients at high risk for placenta accreta spectrum (PAS) disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29136274" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Diagnostic accuracy of magnetic resonance imaging in detecting the severity of abnormal invasive placenta: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23288834" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Morbidly adherent placenta: evaluation of ultrasound diagnostic criteria and differentiation of placenta accreta from percreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26214694" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Three-Dimensional Power Doppler Ultrasonography for Diagnosing Abnormally Invasive Placenta and Quantifying the Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12523606" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The early sonographic appearance of placenta accreta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21907956" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Screening for placenta accreta at 11-14 weeks of gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31788885" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Value of first-trimester ultrasound in prediction of third-trimester sonographic stage of placenta accreta spectrum disorder and surgical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32374433" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Prospective First-Trimester Ultrasound Imaging of Low Implantation and Placenta Accreta Spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26657748" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Sonographic Findings of Morbidly Adherent Placenta in the First Trimester.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33345909" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Early prediction of placenta accreta spectrum in women with prior cesarean delivery using transvaginal ultrasound at 11 to 14 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23091257" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Identifying sonographic markers for placenta accreta in the first trimester.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34837427" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : First-trimester ultrasound diagnostic features of placenta accreta spectrum in low-implantation pregnancy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
